newsfilter
← Latest News
GlobeNewswire·

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Advancing IND-enabling activities for lead program in diabetes, SIG-002, with plans to conduct non-human primate studies in second half of 2023 SIG-002 demonstrated efficacy and durability in in vivo mouse models for up